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Abstract 
Background: We investigated the serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 
3-methoxy-4-hydroxyphenylglycol (MHPG) levels in patients with chronic schizophrenia.
Methods: Sixty-eight patients who met the DSM-IV-TR criteria and had a chronic schizophrenia (CS) duration of 
≥ 5 years were enrolled. Their serum brain-derived BDNF and proBDNF levels were measured by enzyme-linked 
immunosorbent assays, and their plasma MHPG levels were analyzed by high-performance liquid chromatography 
with electrochemical detection.
Results: The plasma MHPG levels were significantly lower in the CS group (3.9  ±  1.8 ng/ml) compared to those in 
the group of 32 age- and sex-matched healthy controls (5.1  ±  2.4 ng/ml). The serum BDNF levels were significantly 
lower in the CS group (8.9  ±  4.8 ng/ml) compared to the control group (12.2.1  ±  6.8 ng/ml). No correlation was 
observed between plasma MHPG and BDNF in the CS group.
Conclusion: These results suggest that hypo-activity of noradrenergic neurons and decreased BDNF secretion exist 
in chronic schizophrenic patients.
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Background
Although plasma 3-methoxy-4-hydroxyphenylglycol 
(MHPG) is used as a measure of peripheral catechola-
minergic activity, an individual’s plasma MHPG level is 
also a good predictor of the central noradrenergic activ-
ity. We reported that plasma MHPG levels were lower 
in schizophrenia patients compared to those in healthy 
controls, and our findings demonstrated that risperi-
done significantly increased plasma MHPG levels, which 
was related to the improvement of negative symptoms 
of schizophrenia in a small sample [1]. We also reported 
that treatment with olanzapine for 4 weeks significantly 
increased plasma BDNF levels in acute schizophrenia 
patients [2]. Taking these findings into account, central 
noradrenergic dysfunctions may play a role in the patho-
genesis of schizophrenia, especially negative symptoms 
and cognitive functions [3].
A recent meta-analysis showed that the plasma/
serum brain-derived neurotrophic factor (BDNF) levels 
in schizophrenia patients were significantly lower than 
those in controls [4]. It is plausible that a decrease in syn-
aptogenesis occurs in patients with schizophrenia. Tak-
ing these findings into account, we hypothesized that a 
reduced noradrenergic system and BDNF exist in schizo-
phrenia patients.
Mature BDNF is initially synthesized as a precur-
sor protein. ProBDNF is converted to mature BDNF by 
extracellular proteases. Mature BDNF is biologically 
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active. In contrast, proBDNF, which is localized intra-
cellularly, serves as an inactive precursor. In short, new 
evidence shows that proBDNF and mature BDNF elicit 
opposing effects via the p75NTR and TrkB receptors, 
respectively, and that both proBDNF and mature BDNF 
play important roles in several physiological functions 
of neurons, which might be related to the pathology 
of psychiatric disorders such as mood disorders and 
schizophrenia [5–9]. Briefly, mature BDNF is related 
to survival of neurons, promotion of growth, and dif-
ferentiation of neurons [10, 11]. On the other hand, 
proBDNF activation includes promotion of myelination 
neuronal migration, neuronal process retraction, and 
neuronal apoptosis [12]. In 2012, Yoshida et al. [9] noted 
that it was initially thought that only secreted mature 
BDNF is biologically active, and that proBDNF serves 
as an inactive precursor. However, as mentioned above, 
proBDNF and BDNF appear to elicit opposing effects 
via the p75NTR and TrkB receptors, respectively, and 
both proBDNF and mature BDNF may play important 
roles in several physiological functions [12]. We recently 
reported that no correlation was however found between 
the Hamilton Rating Scale for Depression (HAMD17) 
scores and proBDNF. In addition, no relationship was 
found between the HAMD17 scores and the proBDNF/
BDNF. Finally, the changes were observed serum levels 
of proBDNF and BDNF during the treatment durations 
with fluvoxamine, which indicates that no association 
exists between serum proBDNF/BDNF and fluvoxamine 
response in MDD patients at least within 4 weeks of the 
treatment [13]. From these findings, MHPG, mature- 
and proBDNF are important molecules for pathogenesis 
of schizophrenia.
To test our hypothesis, we investigated the relationship 
among the plasma levels of a noradrenaline metabolite 
(MHPG), serum BDNF levels, positive and negative syn-
drome scale (PANSS) scores, and global assessment of func-
tioning (GAF) scores in patients with chronic schizophrenia. 
In addition, this is the first report investigating plasma 
proBDNF levels in patients with chronic schizophrenia.
Methods
The subjects were 68 Japanese chronic schizophrenia 
patients (42 males and 26 females) treated at the Univer-
sity Hospital of the University of Occupational and Envi-
ronmental Health, all of whom fulfilled the Diagnostic and 
Statistical Manual of Mental Disorders, fourth Edition, 
Text Revision (DSM-IV-TR) criteria for schizophrenia. The 
treatment durations were all ≥5  years. Their ages ranged 
from 33 to 70 (mean  ±  SD  =  48  ±  9) years. Their dura-
tion of illness ranged from 5 to 40 (mean  ±  SD  =  18  ±  9) 
years. Thirty-two age- and sex-matched healthy subjects 
(age: range 29–68  years, mean  ±   SD  =   47  ±   11  years; 
20 males and 12 females) were also examined. All enrolled 
subjects did not have history of physical diseases; i.e., rheu-
matoid arthritis, hypertension, chronic kidney disease, car-
diovascular disease, metabolic syndrome, cancer, atopic 
diseases, and the subjects did not take statins, aspirin, 
estradiol, dietary supplements such as vitamin E, vitamin 
A, vitamin B12, folic acid, zinc, omega-3 fatty acids, and 
ginko biloba.
The severity of the patients’ clinical symptoms was 
evaluated using the PANSS and GAF. The patients’ 
plasma concentrations of MHPG were analyzed by 
high-performance liquid chromatography with electro-
chemical detection (HPLC-ECD) as described [13]. Their 
serum levels of BDNF and proBDNF were assayed with a 
sandwich enzyme-linked immunosorbent assay (ELISA) 
as described [10].
The study protocol was approved by the Ethics Com-
mittee of the University of Occupational and Environ-
mental Health. Written informed consent was obtained 
from all patients and controls.
Statistical analysis
A non-paired t test was used to compare the plasma lev-
els of MHPG and serum levels of BDNF or proBDNF 
between the chronic schizophrenia and control groups. 
The relationships between pairs of variables were exam-
ined using Person’s correlation coefficients. Significance 
of the results was set at p < 0.05.
Results
Medications of chronic schizophrenia patients
The medications of the chronic schizophrenia patients 
are listed in Table 1.
Plasma MHPG levels of the chronic schizophrenia patients 
and healthy controls
The plasma MHPG levels were significantly lower in 
the chronic schizophrenia (CS) group (4.4  ±   1.6 ng/ml) 
compared to the age- and sex-matched control group 
(6.8  ±  2.0 ng/ml) (t  =  −6.602, p  =  0.0000).
Table 1 Antipsychotic drugs prescribed for the patients
Antipsychotic drug Range, dose (mean ± SD) mg/
day
N of patients
Risperidone 2–8 (4.1 ± 2.3) 24
Olanzapine 5–20 (13.4 ± 6.1) 22
Aripiprazole 6–30 (17.4 ± 5.9) 24
Quetiapine 50–650 (372.6 ± 142.8) 8
Haloperidole 1–6 (2.4 ± 1.6) 2
Levomepromazine 50–200 (71.3 ± 49.2) 8
Zotepine 50–100 (69.4 ± 12.7) 2
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Serum BDNF levels of the chronic schizophrenia patients 
and healthy controls
The serum BDNF levels were significantly lower in the CS 
group (10.2  ±   2.9 ng/ml) compared to the healthy con-
trols (11.9  ±  4.3 ng/ml) (t  =  −2.447, p  =  0.016).
Serum proBDNF levels of the chronic schizophrenia 
patients and healthy controls
No significant difference in serum proBDNF levels was 
revealed between the CS group (4.6   ±   2.1  ng/ml) and 
controls (4.7  ±  2.1 ng/ml) (t  =  −0.064, p  =  0.9491).
Correlation between plasma MHPG levels and serum BDNF 
levels in the chronic schizophrenia patients
No correlation was observed between the plasma 
MHPG levels and serum BDNF levels in the CS patients 
(r  =  0.176, p  =  0.392) (Fig. 1).
Correlation between plasma MHPG levels and serum 
proBDNF in the chronic schizophrenia patients
No correlation exists between plasma MHPG levels and 
serum proBDNF levels in the chronic schizophrenia 
patients (r  =  0.099, p  =  0.641) (Fig. 2).
No correlation between plasma MHPG levels and the 
PANSS scores
No correlation was observed between the plasma MHPG 
levels and any scores on the PANSS among the chronic 
schizophrenia patients (Table 2).
No correlation between serum BDNF and the PANSS scores
No correlations were found between serum BDNF 
and any scores on the PANSS among the CS patients 
(Table 3).
No correlation between serum proBDNF and the PANSS 
scores
No correlations were found between serum proBDNF 
and any scores on the PANSS among the chronic schizo-
phrenia patients (Table 4).
No correlation between plasma MHPG and the GAF scores
No correlation was found between plasma MHPG 
(r   =   −0.104, p   =   0.292) and the GAF scores in the 
chronic schizophrenia group.
Discussion
The main findings in the present study were that any 
correlations were not observed between serum BDNF, 
proBDNF, or plasma MHPG and the PANSS scores in 
the 68 chronic schizophrenia patients. No difference was 
found in the serum proBDNF between the two groups. 
















































Fig. 2 Correlation between plasma MHPG and proBDNF
Table 2 Correlations between  the serum BDNF and  the 
PANSS scores
BDNF PANP PANN PANG PANT
BDNF 1.0000 −0.051 0.0223 0.0848 0.024
PANP −0.051 1.0000 −0.315 −0.253 0.4295
PANN 0.0223 −0.315 1.0000 0.1072 0.5413
PANG 0.0848 −0.253 0.1072 1.0000 0.4481
PANT 0.024 0.4295 0.5413 0.4481 1.0000
Table 3 Correlations between  the serum proBDNF level 
and the PANSS scores
proBDNF PANP PANN PANG PANT
proBDNF 1.0000 0.0855 −0.062 −0.025 0.009
PANP 0.0855 1.0000 −0.315 −0.253 0.4295
PANN −0.062 −0.315 1.0000 0.1072 0.5413
PANG −0.025 −0.253 0.1072 1.0000 0.4481
PANT 0.009 0.4295 0.5413 0.4481 1.0000
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significantly lower in the chronic schizophrenia patients 
compared to the healthy controls.
We reported in a preliminary study that plasma MHPG 
concentrations in patients with schizophrenia were lower 
than those in healthy subjects. The findings of the present 
study reconfirmed our preliminary results, especially the 
findings in the chronic schizophrenia patients. It is pos-
sible that noradrenergic activity decreases in chronic 
schizophrenia [14–16]. In addition, clozapine and risp-
eridone treatment increased plasma noradrenaline levels. 
Taking these findings together, it appears that the hypo-
activity of noradrenergic neurons may exist in chronic 
schizophrenia patients and atypical antipsychotic drugs 
may enhance noradrenergic functions. However, our pre-
sent revealed no correlations between the plasma levels 
of MHPG or serum BDNF and any scores on the PANSS. 
One point at any situations of the patients and/or antip-
sychotic medications might explain the present results.
Chen et  al. [17] reported that the application of 
noradrenaline in embryonic hippocampal neurons 
increased the serum levels of BDNF and phosphoryl-
ated tropomyosin receptor kinase (TrkB), and that these 
increases were prevented by extracellular signal-regu-
lated kinase (ERK) and phosphatidylinositol 3-kinase 
inhibitors (PI-3K). They also showed that noradrenaline-
induced increases in phospho-ERK2 and PI-3K were 
each suppressed by a PI-3K and mitogen-activated pro-
tein kinase inhibitor, respectively. In addition, the phos-
phorylation of cAMP-response element-binding protein 
(CREB) was also increased by noradrenaline and was 
reduced to baseline levels by MAPK and PI-3K inhibi-
tors. In addition, both the MAPK and PI-3K inhibitors 
suppressed the phosphorylation of both TrkB and CREB. 
Taking all of these results into account, it appears that the 
noradrenaline-evoked BDNF expression leads a cyclic 
pathway, reminiscent of a positive feedback loop.
The results of another study elucidated an in  vitro 
model of the intracellular signaling mechanisms acti-
vated by noradrenaline—via ligand G-protein-coupled 
receptor-to-BDNF-receptor tyrosine kinases transac-
tivation — that is putatively thought to occur in vivo as 
a result of excitatory neural activity [18]. Astrocytes as 
an active part of the tripartite synapse can respond to 
the synoptically released neurotransmitters. BDNF is 
produced by astrocytes and neurons. Monoamines are 
able to potently and transiently increase BDNF cellular 
contents [19]. Taken together, these findings indicate a 
deficiency of noradrenaline brought to reduced BDNF 
levels in chronic schizophrenia; however, we observed 
no correlation between the plasma levels of MHPG 
and serum BDNF, which may be plausible that the 
noradrenaline function does not directly influence the 
BDNF level. In other words, it is possible that key mol-
ecules that regulate the balance between noradrenaline 
and BDNF might exist. We also observed that although 
treatment with an atypical antipsychotic drug increased 
plasma MHPG levels, it did not alter plasma BDNF lev-
els [1, 2, 20].
The serum proBDNF level in chronic schizophrenia 
remains unknown. Yamamoto et  al. [21] reported that 
matrix metalloproteinase-9, which plays a role in the 
conversion of proBDNF to mature BDNF, was signifi-
cantly increased in patients with schizophrenia.
In addition, noradrenergic functions and BDNF were 
not related to the GAF scores of the present patients 
with chronic schizophrenia, indicating that both of the 
noradrenergic functions do not reflect the social activi-
ties of the chronic schizophrenia patients.
The present study has several limitations. This was a 
cross-sectional study, and all of the chronic schizophre-
nia patients were being treated with several medications; 
i.e., antipsychotics, mood stabilizers, and benzodiaz-
epines. Thus, the medications might have influenced the 
results. Exercise, stress exposure, menstrual cycle, body 
mass index, and dietary composition also influenced the 
data. Finally, we did not check for the functional imaging 
of brain areas, where BDNF is concentrated.
In conclusion, any correlations were not found between 
serum BDNF, proBDNF, or plasma MHPG and the 
PANSS scores in the 68 chronic schizophrenia patients. 
We also reconfirmed that serum BDNF and plasma 
MHPG levels were significantly reduced in the 68 chronic 
schizophrenia patients compared to healthy controls.
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Table 4 Correlations between  the plasma MHPG levels 
and the PANSS scores
MHPG PANP PANN PANG PANT
MHPG 1.0000 −0.199 0.0655 0.1339 −0.035
PANP −0.199 1.0000 −0.315 −0.253 0.4295
PANN 0.0655 −0.315 1.0000 0.1072 0.5413
PANG 0.1339 −0.253 0.1072 1.0000 0.4481
PANT −0.035 0.4295 0.5413 0.4481 1.0000
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